Physician profile
Michael D Stormont
NPI 1811221153
$2,930.30
in general payments reported to CMS, 2019-2025
28 companies · $626 in 2025
The $626 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $462 · 2021: $445 · 2022: $122 · 2023: $484 · 2024: $490 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,585 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,584.69 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $921.50 | 2021-2025 | Ubrelvy, Vraylar |
| Novo Nordisk INC | $221.82 | 2019-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $141.54 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Indivior INC. | $139.38 | 2019-2025 | Sublocade |
| Axsome Therapeutics, INC. | $138.39 | 2024-2025 | Auvelity |
| Lilly USA, LLC | $119.21 | 2019-2024 | Emgality, Jardiance, Zepbound |
| Mdd US Operations, LLC | $118.21 | 2019-2020 | |
| Teleflex LLC | $115.95 | 2025 | Urolift |
| Amarin Pharma, INC. | $109.25 | 2019-2021 | |
| Abbott Laboratories | $88.31 | 2023-2025 | Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $84.43 | 2021-2025 | |
| Orexo US, INC. | $79.75 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.98 | 2019-2024 | Trintellix |
| Currax Pharmaceuticals LLC | $67.53 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.16 | 2019-2024 | Xifaxan, Trulance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $57.11 | 2019-2023 | Vivitrol |
| Pfizer INC. | $54.60 | 2019-2020 | |
| Braeburn INC. | $53.04 | 2023-2025 | Brixadi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.80 | 2020-2021 | |
| Allergan, INC. | $43.98 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $37.59 | 2020-2023 | Austedo Xr |
| Neurocrine Biosciences, INC. | $36.72 | 2023 | Ingrezza |
| Biohaven Pharmaceuticals, INC. | $25.81 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $24.18 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $22.57 | 2024 | Spravato |
| Dexcom, INC. | $16.61 | 2023 | Dexcom G6 Transmitter |
| Uswm, LLC | $16.50 | 2021 | |
| Jazz Pharmaceuticals INC. | $13.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stormont listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.